A.J. Lacave

745 total citations
16 papers, 514 citations indexed

About

A.J. Lacave is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, A.J. Lacave has authored 16 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in A.J. Lacave's work include Cancer Treatment and Pharmacology (6 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). A.J. Lacave is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). A.J. Lacave collaborates with scholars based in Spain, Belgium and Netherlands. A.J. Lacave's co-authors include G.H. Blijham, Harry Bleiberg, M. Namer, Tarek Sahmoud, Pietro De Besi, Laurence Collette, Francesca Gay, B Paillot, Laurent Bedenne and Thierry Conroy and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A.J. Lacave

16 papers receiving 492 citations

Peers

A.J. Lacave
O. Dalesio Netherlands
Özden Altundağ Türkiye
V. Merz Switzerland
C. A. Meanwell United Kingdom
N. Tsavaris Greece
Jess Frank United States
Mina Yu South Korea
Stylianos Giassas Greece
Clive Stubbs United Kingdom
Emir Charles Roach Türkiye
O. Dalesio Netherlands
A.J. Lacave
Citations per year, relative to A.J. Lacave A.J. Lacave (= 1×) peers O. Dalesio

Countries citing papers authored by A.J. Lacave

Since Specialization
Citations

This map shows the geographic impact of A.J. Lacave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.J. Lacave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.J. Lacave more than expected).

Fields of papers citing papers by A.J. Lacave

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.J. Lacave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.J. Lacave. The network helps show where A.J. Lacave may publish in the future.

Co-authorship network of co-authors of A.J. Lacave

This figure shows the co-authorship network connecting the top 25 collaborators of A.J. Lacave. A scholar is included among the top collaborators of A.J. Lacave based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.J. Lacave. A.J. Lacave is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Viéitez, José María, et al.. (2011). A phase II study with perioperative modified docetaxel, cisplatin, and capecitabine (mDCX) in resectable gastroesophageal adenocarcinoma.. Journal of Clinical Oncology. 29(15_suppl). e14554–e14554. 2 indexed citations
3.
Viéitez, José María, Carlos García Girón, C. Madroñal, et al.. (2004). Definitive results of a phase II study with carboplatin (CBDCA) plus etoposide (VP16) and sequential topotecan in small cell lung cancer (SCLC). (an INTER-GON trial). Journal of Clinical Oncology. 22(14_suppl). 7266–7266. 1 indexed citations
4.
Esteban, Emilio, Isabel Palacio, Yolanda Fernández, et al.. (2003). Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study. Breast Cancer Research and Treatment. 80(3). 257–265. 1 indexed citations
5.
Wagenaar, Hendrik, N. Colombo, Ignace Vergote, et al.. (2001). Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study. Gynecologic Oncology. 81(3). 348–354. 57 indexed citations
6.
7.
Wagenaar, Hendrik, S. Pecorelli, Costantino Mangioni, et al.. (2001). Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. European Journal of Cancer. 37(13). 1624–1628. 14 indexed citations
8.
Esteban, Emilio, et al.. (2000). A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Research and Treatment. 62(2). 127–133. 5 indexed citations
9.
Esteban, Emilio, A.J. Lacave, Norberto Corral, et al.. (1999). Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Research and Treatment. 58(2). 141–150. 9 indexed citations
10.
Bleiberg, Harry, Thierry Conroy, B Paillot, et al.. (1997). Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. European Journal of Cancer. 33(8). 1216–1220. 235 indexed citations
11.
Neijt, J.P., et al.. (1995). Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. British Journal of Cancer. 71(1). 106–108. 18 indexed citations
12.
13.
Durrant, K.R., C. Mangioni, A.J. Lacave, et al.. (1990). Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: A phase II study of the EORTC gynaecological cancer cooperative group (GCCG). Gynecologic Oncology. 37(3). 359–362. 37 indexed citations
14.
Hidalgo, O. Fernández, et al.. (1989). 120 Hours Simultaneous Infusion of Cisplatin and Fluorouracil in Metastatic Breast Cancer. American Journal of Clinical Oncology. 12(5). 397–401. 29 indexed citations
15.
Wils, J., Harry Bleiberg, G.H. Blijham, et al.. (1985). Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. European Journal of Cancer and Clinical Oncology. 21(2). 191–194. 34 indexed citations
16.
Buesa, J., et al.. (1984). Phase I trial of intermittent high-dose dacarbazine.. PubMed. 68(3). 499–504. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by O. Dalesio Breakdown of academic impact, for papers by Özden Altundağ Breakdown of academic impact, for papers by V. Merz Breakdown of academic impact, for papers by C. A. Meanwell Breakdown of academic impact, for papers by N. Tsavaris Breakdown of academic impact, for papers by Jess Frank Breakdown of academic impact, for papers by Mina Yu Breakdown of academic impact, for papers by Stylianos Giassas Breakdown of academic impact, for papers by Clive Stubbs Breakdown of academic impact, for papers by Emir Charles Roach
Rankless by CCL
2026